VolitionRX Limited (VNRX) Covered Calls

VolitionRx Limited (VNRX) is a multi-national epigenetics company focused on developing blood-based diagnostic tests. Using its proprietary Nucleosomics platform, the company identifies and measures nucleosomes in the bloodstream to help detect and monitor life-altering diseases. Its portfolio includes diagnostic solutions for various cancers and diseases associated with NETosis, such as sepsis, for both human and veterinary applications.

You can sell covered calls on VolitionRX Limited to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for VNRX (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

VolitionRx Limited is an innovation-driven biotechnology company dedicated to improving patient outcomes through early disease detection. Its core technology, Nucleosomics, focuses on the study of nucleosomes—fundamental structures of DNA—within bodily fluids. By developing cost-effective, non-invasive diagnostic assays, the company seeks to provide tools that assist clinicians in diagnosing, monitoring, and managing complex health conditions.

The company operates across two primary pillars: human diagnostics and veterinary medicine. Its "Nu.Q" product line is a key focus, offering diagnostic tests that are increasingly finding utility in routine clinical practice. Furthermore, VolitionRx is expanding its commercial footprint through strategic partnerships—such as its collaboration with Fujifilm Vet Systems for automated veterinary diagnostics—and is advancing its "Capture-Seq" technology for high-precision, early-stage cancer detection.

Competitive Landscape

VolitionRx operates in the high-stakes, capital-intensive biotechnology and diagnostics sector. It faces significant competition from both large-scale medical device manufacturers and specialized biotech innovators. Investors tracking the diagnostics and precision medicine space often monitor highly liquid benchmarks such as Illumina, a leader in DNA sequencing, or broader healthcare sector ETFs like the Health Care Select Sector SPDR Fund (XLV). These entities provide broader exposure to the life sciences industry and offer the deep, active options markets required for sophisticated hedging or directional strategies, contrasting with the higher volatility and specific risks associated with micro-cap biotech firms like VNRX.

Strategic Outlook and Innovation

The strategic roadmap for VolitionRx is focused on commercializing its diagnostic pipeline and achieving sustainable regulatory milestones. The company is actively working toward securing reimbursement pathways for its Nu.Q cancer assays, a critical step for mass-market adoption. Innovation remains central to its mission, with ongoing R&D aimed at refining its "Capture-Seq" and other epigenetic platforms to enhance the sensitivity and specificity of its liquid biopsy tests.

As VolitionRx navigates the regulatory and clinical hurdles inherent in biotechnology, its focus remains on scaling its distribution networks and demonstrating the cost-effectiveness of its tests. By bridging the gap between advanced epigenetic research and practical, clinical diagnostic tools, the company aims to establish itself as a vital player in the evolution of precision medicine and veterinary diagnostics.

Want more examples? VNQI Covered Calls | VNT Covered Calls